Clinical Trial Update: V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) [Phase 2]

View source ↗

Summary

Phase 2 immunogenicity study of the HPV vaccine V501 in females aged 9 to 17 completed; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HPV Infections | Phase 2 | Status: COMPLETED | Results posted: 2010-08-18